A5061972493- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- vaccines and immunoinformatics approaches
- Complement system in diseases
- Nanoplatforms for cancer theranostics
- Phagocytosis and Immune Regulation
- Medication Adherence and Compliance
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- Animal Virus Infections Studies
- Cancer Research and Treatments
- Adenosine and Purinergic Signaling
- Neuroblastoma Research and Treatments
- Ferroptosis and cancer prognosis
- Nuclear Physics and Applications
- RNA Interference and Gene Delivery
- Radiation Effects and Dosimetry
- Endoplasmic Reticulum Stress and Disease
- IL-33, ST2, and ILC Pathways
- Immune Response and Inflammation
- Ultrasound and Hyperthermia Applications
University of Lausanne
2023-2025
Navarre Institute of Health Research
2019-2024
Universidad de Navarra
2019-2024
Ludwig Cancer Research
2023-2024
Swiss Cancer Center Léman
2023-2024
University Hospital of Lausanne
2023-2024
Clinica Universidad de Navarra
2024
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2020-2022
Centro de Investigación Biomédica en Red
2022
Icahn School of Medicine at Mount Sinai
2021
Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not investigated. Our aim was analyze whether tumors in HCC patients contain neoantigens suitable future use therapeutic Methods Whole-exome sequencing RNAseq were performed cohort of fourteen submitted surgery...
The high metabolic activity and insufficient perfusion of tumors leads to the acidification tumor microenvironment (TME) that may inhibit antitumor T cell activity. We found pharmacological inhibition acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4'-diisothiocyanatostilbene-2,2'-disulfonicacid (DIDS) enhancedCD4+ andCD8+ function upon TCR activation in vitro, especially under low pH conditions. In vivo, DIDS administration delayed B16OVA growth immunocompetent mice as...
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 12</p>
<p>Supplementary Figure 10</p>
<p>Supplementary Figure 14</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 13</p>
<p>Supplementary Figure 15</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 11</p>
<div>Abstract<p>The precise mechanisms by which the complement system contributes to establishment of an immunosuppressive tumor microenvironment and promotes progression remain unclear. In this study, we investigated expression function C5a receptor 1 (C5aR1) in human mouse cancer-associated dendritic cells (DC). First, observed overexpression C5aR1 tumor-infiltrating DCs, compared with DCs from blood or spleen. was restricted type 2 conventional monocyte-derived displayed a...
<p>Supplementary Figure 6</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 8</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 9</p>
<p>Supplementary Figure 7</p>
Therapies based on immune checkpoint inhibitors (ICPI) have yielded promising albeit limited results in patients with hepatocellular carcinoma (HCC). Vaccines been proposed as combination partners to enhance response rates ICPI. Thus, we analyzed the combined effect of a vaccine TLR4 ligand cold-inducible RNA binding protein (CIRP) plus Mice were immunized vaccines containing ovalbumin linked CIRP (OVA-CIRP), or without ICPI, and antigen-specific responses therapeutic efficacy tested...
Immune checkpoint inhibitor (ICI)-based immunotherapy in triple negative breast cancer (TNBC) is achieving limited therapeutic results, requiring the development of more potent strategies. Combination ICI with vaccination strategies would enhance antitumor immunity and response rates to patients having poorly infiltrated tumors. In heavily mutated tumors, neoantigens (neoAgs) resulting from tumor mutations have induced responses when used as vaccines. Thus, our aim was identification...